Showing 1311-1320 of 21420 results for "".
- Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectivenesshttps://reachmd.com/news/interim-estimates-of-2025-26-seasonal-influenza-vaccine-effectiveness/2486668/Key Takeaways In interim estimates, vaccine effectiveness against influenza-associated outpatient visits was 38%–41% in children and adolescents and 22%–34% in adults; effectiveness against influenza-associated hospitalization was 41% and 30%, respectively.
- Insurance And Employment After Medicaid Expansion Work Ruleshttps://reachmd.com/news/insurance-and-employment-after-medicaid-expansion-work-rules/2486663/Researchers conducted a quasi-experimental difference-in-differences study to evaluate how Medicaid expansion with work requirements affected ins
- Peanut Oral Immunotherapy Value Assessed In Childrenhttps://reachmd.com/news/peanut-oral-immunotherapy-value-assessed-in-children/2486660/Key Takeaways This economic evaluation compared probiotic and peanut oral immunotherapy (PPOIT), peanut oral immunotherapy (OIT), and no treatment for children with peanut allergy. Both PPOIT and OIT were cost-effective compared with no treatment when
- Antibiotic Use During GI Infection Linked to Higher IBS Riskhttps://reachmd.com/news/antibiotic-use-during-gi-infection-linked-to-higher-ibs-risk/2486672/Key Takeaways Pooled estimates suggested higher IBS incidence among patients who received antibiotics than among those who did not, with very high heterogeneity across studies. In analyses limited to gastrointestinal infections, the pooled IRR was 1.71
- GBM AGILE Phase II/III Bayesian Randomized Platform Trialhttps://reachmd.com/news/gbm-agile-phase-iiiii-bayesian-randomized-platform-trial/2486655/Key Takeaways In GBM AGILE, regorafenib did not improve overall survival versus control in either newly diagnosed unmethylated or recurrent glioblastoma and enrollment stopped early for limited efficacy. The trial used a phase II/III Bayesian adaptive
- Ravulizumab in IgA Nephropathy: Phase 2 Trial Readouthttps://reachmd.com/news/ravulizumab-in-iga-nephropathy-phase-2-trial-readout/2486671/Key Takeaways During the randomized period, ravulizumab was associated with a greater reduction in proteinuria than placebo at week 26 (−41.9% vs −16.8%; treatment effect 30.1%; P = 0.005). Investigators reported a trend toward eGFR stabilization (leas
- IEC Establishes Global Definitions for AD Disease Control and Remissionhttps://reachmd.com/news/iec-establishes-global-definitions-for-ad-disease-control-and-remission/2486652/A new consensus statement from the International Eczema Council (IEC) proposes standardized definitions for low disease activity (LDA), very low disease activity (vLDA), and remission in atopic dermatitis (AD), addressing what authors noted as a longstanding gap in
- Evaluating a Peer Navigator Intervention for Opioid-Related Overdosehttps://reachmd.com/news/peer-navigator-intervention-opioid-overdose/2486633/Key Takeaways: In a randomized four-site emergency department trial, investigators found no significant difference in opioid-related adverse events between a peer navigator intervention and site-directed care. The Relay model began in the emergency dep
- AI Dermatology Tools Improve Patient Diagnostic Accuracy in Survey Studyhttps://reachmd.com/news/ai-dermatology-tools-improve-patient-diagnostic-accuracy-in-survey-study/2486637/An AI-powered dermatology application was associated with improved consumer understanding of skin conditions, according to new research published in JAMA Dermatology. The study includ
- Remimazolam Matches Propofol In Postoperative ICU Sedation Trialhttps://reachmd.com/news/remimazolam-matches-propofol-in-postoperative-icu-sedation-trial/2486614/A paper reports results from a multicenter, randomized, single-blind, actively controlled phase 3 non-inferiority trial comparing remimazolam tosylate with propofol, with sedation success rates